GlassScriptPhysician profile
Carol B Emerson
NPI 1922412477
$6,872.24
in general payments reported to CMS, 2019-2025
19 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,285 · 2022: $1,726 · 2023: $2,226 · 2024: $574 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $805 · Consulting Fee: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $805.00 |
| Consulting Fee | $172.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,688.15 | 2022-2025 | Azstarys |
| Abbvie INC. | $1,186.93 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $763.01 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $568.76 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $499.78 | 2021-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $409.89 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Idorsia Pharmaceuticals US INC | $289.25 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $250.57 | 2021-2022 | |
| Alkermes, INC. | $240.53 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $219.56 | 2022-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $161.93 | 2025 | Jornay Pm |
| Lundbeck LLC | $156.63 | 2021-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $134.32 | 2022-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $89.54 | 2023 | Spravato |
| Neurocrine Biosciences, INC. | $68.20 | 2022-2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $61.68 | 2025 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $33.57 | 2024-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $28.63 | 2025 | Cobenfy |
| Tempus Ai, INC | $21.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Emerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.